RAC 1.55% $1.31 race oncology ltd

RAC - Charts & Price Action, page-1422

  1. 2,504 Posts.
    lightbulb Created with Sketch. 9413
    If they are experienced using bisantrene it does rather narrow down who they could be or they are very old.

    The key to valuing bisantrene is to treat it as effectively two different drugs:

    1. A better anthracycline (eg doxorubicin, etc). There is real value here comes from the anthracyclines not being nice drugs which have some serious long term problems especially to the heart. Bisantrene is used at high doses (250mg/m2/day) to kill the cancer via DNA damage and Topo II inhibition (standard chemo). There is lots of clinical data supporting the use of bisantrene this way.

    2. A FTO targeted agent. The value here comes from using bisantrene at a low dose to inhibit the FTO protein. The FTO protein appears to be overexpressed in a wide range of different cancers and its inhibition is a very exciting new target in oncology. There is no clinical data support the use bisantrene this way, but the preclinical data is very encouraging.



 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.31
Change
0.020(1.55%)
Mkt cap ! $217.2M
Open High Low Value Volume
$1.31 $1.31 $1.26 $71.25K 55.65K

Buyers (Bids)

No. Vol. Price($)
1 200 $1.27
 

Sellers (Offers)

Price($) Vol. No.
$1.31 5950 3
View Market Depth
Last trade - 16.10pm 26/04/2024 (20 minute delay) ?
Last
$1.31
  Change
0.020 ( 2.18 %)
Open High Low Volume
$1.30 $1.31 $1.26 10789
Last updated 15.59pm 26/04/2024 ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.